India’s first mRNA vaccine against Covid-19 from Gennova gets DCGI approval
Gennova's vaccine will be available for adults above 18 years of age. It will be a two-dose vaccine that will be administered intramuscularly at 28 days apart
Gennova's vaccine will be available for adults above 18 years of age. It will be a two-dose vaccine that will be administered intramuscularly at 28 days apart
Serum Institute chief executive Adar Poonawalla, during a media event today, said the company has 200 million doses of vaccine stock available currently.
Covid-19 vaccines Corbevax and Covovax, and anti-viral medication Molnupiravir have been granted emergency use authorisation by the CDSCO.
WHO chief scientist Soumya Swaminathan congratulated Serum Institute, Adar Poonawalla and Novavax for offering one more highly effective and safe vaccine.
Besides Covishield, four more Covid-19 vaccines are under preparation at the world’s largest vaccine company in Pune as demand from across the globe spikes.